<DOC>
	<DOCNO>NCT01058616</DOCNO>
	<brief_summary>The study evaluate safety profile LTX-315 lytic-peptide show effect animal model kill cancer tumour inject directly tumour . The study also monitor immunological response body injection LTX-315 .</brief_summary>
	<brief_title>Dose-escalation Study LTX-315 Patients With Transdermally Accessible Tumour</brief_title>
	<detailed_description>A phase I study initial concentration/volume escalate part follow expanded cohort recommend dose ( RD ) . This open label , multicentre study assess safety , tolerance , PK efficacy LTX-315 inject directly transdermally accessible tumour day 1 8 . Additional weekly injection may make , total 6 injection . Subjects may include study meet follow criterion : 1 . Histologically confirm malignant tumour 2 . Transdermally accessible lesion ( close skin ) 3 . Age â‰¥ 18 year 4 . ECOG Performance status ( PS ) : 0 - 2 5 . Life expectancy : At least 3 month The primary objective study evaluate safety profile LTX-315 assessment adverse event abnormal laboratory value record study determine recommend dose LTX-315 . The secondary objective study preliminarily assess anti-tumour activity LTX-315 patient transdermally accessible tumour , monitor immunological response , pharmacokinetic assessment , determine duration response .</detailed_description>
	<criteria>Histologically confirm malignant tumour . Transdermally accessible lesion ( close skin ) 1 5 cm diameter . ECOG Performance status ( PS ) : 0 2 Life expectancy : At least 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>